An investigation on behalf of investors in Vascular Solutions, Inc. (NASDAQ:VASC) shares over potential wrongdoing at Vascular Solutions was announced and NASDAQ:VASC stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 12/16/2014 -- An investigation on behalf of current long-term investors in shares of Vascular Solutions, Inc. (NASDAQ:VASC) shares was announced over potential breaches of fiduciary duties by certain officers and directors at Vascular Solutions.
Investors who purchased shares of Vascular Solutions, Inc. (NASDAQ:VASC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Vascular Solutions officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
On November 13, 2014, a federal grand jury indicted Vascular Solutions' CEO, Howard Root, on charges he conspired to sell a varicose-vein treatment device for unapproved uses. The nine count indictment alleges Vascular Solutions, Inc improperly marketed its Vri-Lase device kit for use on veins deep in the leg, even though it was only approved for use on superficial blood vessels and a clinical trial showed adverse events when Vari-Lase was used on deeper veins.
Shares of Vascular Solutions, Inc dropped from almost $31 per share on November 13, 2014, to as low as $23.23 per share on November 13, 2014.
On November 14, 2014, NASDAQ:VASC shares closed at $
per share.
Those who purchased shares of Vascular Solutions, Inc. (NASDAQ:VASC), have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com